Lakefront Biotherapeutics American Depositary Shares
LKFT
81 hedge funds and large institutions have $857M invested in Lakefront Biotherapeutics American Depositary Shares in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 24 reducing their positions, and 10 closing their positions.
670% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $3.52M
118% more capital invested
Capital invested by funds: $393M → $857M (+$464M)
26.43% more ownership
Funds ownership: 20.73% → 47.16% (+26%)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
3% more funds holding
Funds holding: 79 → 81 (+2)
0% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$40.7M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$21.8M |
| 3 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$3.26M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.08M |
| 5 |
Morgan Stanley
New York
|
+$1.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$23M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$7.77M |
| 3 |
NM
Newtyn Management
New York
|
-$6.41M |
| 4 |
Millennium Management
New York
|
-$6.27M |
| 5 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$3.12M |
LKFT Hedge Fund Activity: Q4 2024 in Review
81 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2024, worth a combined $857M — up 118% from $393M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new LKFT positions and 10 closed out — a net gain of 2 holders — while 24 added to existing stakes and 24 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $40.7M. The largest seller was Logos Global Management, exiting entirely with an estimated $23M sold.
- 81 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2024, up from 79 in Q3 2024.
- Funds reported $857M of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2024, up 118% quarter-over-quarter.
- 12 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2024 and 10 closed out, a net change of +2 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2024 was Tang Capital Management, an estimated $40.7M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2024 was Logos Global Management, an estimated $23M sold.
Based on aggregated 13F filings for Q4 2024.